.Competing rate of interests.R.S., M.S., H.G. as well as A.A.R. are planners of the 1M1M project.
H.G. and A.A.R. are panel of supervisors participants and R.S., M.S.
and also A.A.R. are members of the clinical advising board of N1C. A.A.R.
discloses job by LUMC, which has patents on exon-skipping innovation, a number of which has actually been actually licensed to BioMarin and also consequently sublicensed to Sarepta. As co-inventor of a number of these licenses, A.A.R. was actually allowed to a portion of royalties.
A.A.R. even further divulges serving as ad hoc consultant for PTC Therapies, Sarepta Therapies, Regenxbio, Dyne Rehabs, Lilly, BioMarin Pharmaceuticals Inc., Eisai, Entrada, Takeda, Splicesense, Galapagos, Sapreme, Italfarmaco and Astra Zeneca. Over the last 5 years, A.A.R.
likewise carried out consulting for Alpha Anomeric. A.A.R. likewise states membership of the clinical advisory boards of Eisai, Hybridize Therapies, Muteness Rehabs, Sarepta Therapeutics, Sapreme and also Mitorx.
Before 5 years, A.A.R. was actually also a medical board of advisers participant for ProQR. Reimbursement for A.A.R.
u00e2 s consulting and also urging tasks is actually spent to LUMC. Before 5 years, LUMC likewise got speaker gratuity coming from PTC Therapeutics, Alnylam Netherlands, Italfarmaco and also Pfizer and also moneying for contract analysis coming from Sapreme, Eisai, Galapagos, Synaffix and Alpha Anomeric. Job financing is acquired from Sarepta Therapies and Entrada using unrestricted grants.
H.G. has nothing at all to divulge in relation to the topics dealt with in this manuscript. Previously 5 years, he has likewise received working as a consultant gratuity coming from UCB.
M.S. acquired consultancy honoraria coming from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly and Solaxa previously 5 years, all unassociated to the here and now manuscript. R.S.
has absolutely nothing to disclose relative to the topics covered within this composition. She has received audio speaker and/or working as a consultant gratuity or even sponsoring additions from Abbvie, Bial, STADA and also Everpharma in the past 5 years.